1946 treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 21:151–159 85. Wong H, Mylrea K, Feber J, Drukker A, Filler G (2006) Prevalence of complications in children with chronic kidney disease according to KDOQI. Kidney Int 70:585–590 86. Fivush BA, Jabs K, Neu AM, Sullivan EK, Feld L, Kohaut E, Fine R (1998) Chronic renal insufficiency in children and adolescents: the 1996 annual report of NAPRTCS. North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 12:328–337 87. Salusky IB, Kuizon BG, Jüppner H (2004) Special aspects of renal osteodystrophy in children. Semin Nephrol 24:69–77 88. Sanchez CP, Kuizon BD, Abdella PA, Jüppner H, Salusky IB, Goodman WG (2000) Impaired growth, delayed ossification, and reduced osteoclastic activity in the growth plate of calcium-supplemented rats with renal failure. Endocrinology 141:1536–1544 89. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD (1996) Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337–349 90. Carrero JJ, Ortiz A, Qureshi AR, Martín-Ventura JL, Bárány P, Heimbürger O, Marrón B, Metry G, Snaedal S, Lindholm B, Egido J, Stenvinkel P, Blanco-Colio LM (2009) Additive effects of soluble TWEAK and inflammation on mortality in hemodi- alysis patients. Clin J Am Soc Nephrol 4:110–118 91. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimbürger O, Cederholm T, Girndt M (2005) IL- 10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia–the good, the bad, and the ugly. Kidney Int 67:1216–1233 92. Stenvinkel P, Pecoits-Filho R, Lindholm B, for the DialGene Consortium (2005) Gene polymorphism association studies in dialysis: the nutrition-inflammation axis. Semin Dial 18:322–330 93. Eleftheriadis T, Kartsios C, Antoniadi G, Kazila P, Dimitriadou M, Sotiriadou E, Koltsida M, Golfinopoulos S, Liakopoulos V, Christopoulou-Apostolaki M (2008) The impact of chronic inflammation on bone turnover in hemodialysis patients. Ren Fail 30:431–437 94. Türk S, Akbulut M, Yildiz A, Gürbilek M, Gönen S, Tombul Z, Yeksan M (2002) Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone mineral density. Nephron 90:188–194 95. Montalbán C, García-Unzueta MT, De Francisco AL, Amado JA (1999) Serum interleukin-6 in renal osteodystropgy: relationship with serum PTH and bone remodeling markers. Horm Metab Res 31:14–17 96. Steddon SJ, McIntyre CW, Schroeder NJ, Burrin JM, Cunningham J (2004) Impaired release of interleukin-6 from human osteoblastic cells in the uraemic milieu. Nephrol Dial Transplant 19:3078–3083 97. Sánchez MC, Bajo MA, Selgas R, Mate A, Sánchez-Cabezudo MJ, López-Barea F, Esbrit P, Martínez ME (2001) Cultures of human osteoblastic cells from dialysis patients: influence of bone turnover rate on in vitro selection of interleukin-6 and osteo- blastic cell makers. Am J Kidney Dis 37:30–37 98. Duarte ME, Carvalho EF, Cruz EA, Lucena SB, Andress DL (2002) Cytokine accumulation in osteitis fibrosa of renal osteodystrophy. Braz J Med Biol Res 35:25–29 Pediatr Nephrol (2011) 26:1937–1946 99. Langub MC Jr, Koszewski NJ, Turner HV, Monier-Faugere MC, Geng Z, Malluche HH (1996) Bone resorption and mRNA expression of IL-6 and IL-6 receptor in patients with renal osteodystrophy. Kidney Int 50:515–520 100. Karsenty G (2006) Convergence between bone and energy homeostasis: leptin regulation of bone mass. Cell Metab 4:341– 348 101. Lieben L, Callewaert F, Bouillon R (2009) Bone and metabo- lism: a complex crosstalk. Horm Res 71(S1):134–138 102. Baek K, Bloomfield SA (2009) Beta-adrenergic blockade and leptin replacement effectively mitigate disuse bone loss. J Bone Miner Res 24:792–799 103. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197–207 104. Cumin F, Baum HP, Levens N (1996) Leptin is cleared from the circulation primarily by the kidney. Int J Obes Relat Metab Disord 20:112–126 105. Sharma K, Considine RV, Michael B, Dunn SR, Weisberg LS, Kurnik BR, Kurnik PB, O'Connor J, Sinha M, Caro JF (1997) Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 51:1980–1985 106. Daschner M, Tönshoff B, Blum WF, Englaro P, Wingen AM, Schaefer F, Wühl E, Rascher W, Mehls O (1998) Inappropriate elevate of serum leptin levels in children with chronic renal failure. European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. J Am Soc Nephrol 9:1074–1079 107. Brown SA, Rosen CJ (2003) Osteoporosis. Med Clin North Am 87:1039–1063 108. Coen G, Ballanti P, Fischer MS, Balducci A, Calabria S, Colamarco L, Di Zazzo G, Lifrieri F, Manni M, Sardella D, Nofroni I, Bonucci E (2003) Serum leptin in dialysis renal osteodystrophy. Am J Kidney Dis 42:1036–1042 109. Cheung W, Yu PX, Little BM, Cone RD, Marks DL, Mak RH (2005) Role of leptin and melanocortin signaling in uremia- associated cachexia. J Clin Invest 115:1659–1665 110. Farooqi IS, Yeo GS, Keogh JM, Aminian S, Jebb SA, Butler G, Cheetham T, O'Rahilly S (2000) Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 106:271–279 111. Cheung W, Vanek C, Iwaniec UT, Turner RT, Klein RF, Mak RH (2007) A novel hypothalamic mechanism in uremic bone disease. Abstract, 39th Annual Meeting American Society of Nephrology, SA-FC006, November 1st-4th, San Francisco, California, USA 112. Bjurholm A, Kreicbergs A, Terenius L, Goldstein M, Schultzberg M (1988) Neuropeptide Y-, tyrosine hydroxylase- and vasoactive intestinal polypeptide-immunoreactive nerves in bone and sur- rounding tissues. Auton Nerv Syst 25:119–125 113. Baldock PA, Sainsbury A, Couzens M, Enriquez RF, Thomas GP, Gardiner EM, Herzog H (2002) Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 109:915–921 114. Patel MS, Elefterios F (2007) The new field of neuroskeletal biology. Calf Tissue Int 80:337–347 115. Adu-Zikri N, El-Fattah AA, Raafat M, Ismail L, Yahya A, Ahmed A, El-Sadek SA, El-Shamaa A, El-Sheikh N (2009) Study of neuropeptide Y and its relation to the cardiovascular complications in end stage renal disease. World J Med Sci 4:22–32